Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,298,375
  • Shares Outstanding, K 282,580
  • Annual Sales, $ 812,030 K
  • Annual Income, $ -68,090 K
  • EBIT $ -46 M
  • EBITDA $ 80 M
  • 60-Month Beta N/A
  • Price/Sales 6.62
  • Price/Cash Flow 12.10
  • Price/Book 9.43

Options Overview Details

View History
  • Implied Volatility 84.35% (-5.21%)
  • Historical Volatility 57.86%
  • IV Percentile 59%
  • IV Rank 38.95%
  • IV High 132.24% on 03/18/26
  • IV Low 53.81% on 01/21/26
  • Expected Move (DTE 9) 3.70 (18.89%)
  • Put/Call Vol Ratio 4.88
  • Today's Volume 506
  • Volume Avg (30-Day) 333
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 6,941
  • Open Int (30-Day) 7,406
  • Expected Range 15.87 to 23.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $-0.02
  • Low Estimate $-0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.28 +19.63%
on 03/30/26
20.05 -2.87%
on 04/08/26
+0.89 (+4.76%)
since 03/06/26
3-Month
16.28 +19.63%
on 03/30/26
29.00 -32.84%
on 01/12/26
-8.77 (-31.06%)
since 01/08/26

Most Recent Stories

More News
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers  

CAI : 19.40 (+3.47%)
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight

CAI : 19.40 (+3.47%)
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches

CAI : 19.40 (+3.47%)
Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panels

CAI : 19.40 (+3.47%)
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

IRVING, Texas , March 25, 2026 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 19.40 (+3.47%)
Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patients

CAI : 19.40 (+3.47%)
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

Highlighting the critical role of Caris GPSai in improving cancer care

CAI : 19.40 (+3.47%)
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer

Caris AI Insights are proprietary and only available to Caris Life Sciences customers  

CAI : 19.40 (+3.47%)
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

IRVING, Texas , March 11, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 19.40 (+3.47%)
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer

Caris AI Insights are proprietary and only available to Caris Life Sciences customers

CAI : 19.40 (+3.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 19.68
2nd Resistance Point 19.28
1st Resistance Point 19.02
Last Price 19.40
1st Support Level 18.36
2nd Support Level 17.96
3rd Support Level 17.70

See More

52-Week High 42.50
Fibonacci 61.8% 32.48
Fibonacci 50% 29.39
Fibonacci 38.2% 26.30
Last Price 19.40
52-Week Low 16.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.